

**ORIGINAL  
RESEARCH**

P. Eisele  
K. Szabo  
M. Griebel  
C. Roßmanith  
A. Förster  
M. Hennerici  
A. Gass



# Reduced Diffusion in a Subset of Acute MS Lesions: A Serial Multiparametric MRI Study

**BACKGROUND AND PURPOSE:** MRI studies have focused on newly developing MS lesions to characterize the early pathology of the disease. DWI is highly sensitive to acute and chronic tissue changes in MS. We characterized the development of acute MS lesions by using DWI in a multiparametric MRI protocol.

**MATERIALS AND METHODS:** Seventy-two consecutive patients presenting with a new symptom with definite MS or a CIS suggestive of central nervous system demyelination were screened with MRI. Patients who showed an acute MRI lesion with a reduction of ADC were studied with serial MRI for up to 4 months after presentation.

**RESULTS:** Ten of 72 screened patients who showed a lesion with a reduced ADC were each examined 4–7 times, resulting in 52 examinations in total. We identified a characteristic sequence of signal-intensity changes: 1) days 0–7: slight T2 hyperintensity and prominent ADC reduction (maximum, –66%), faint or no enhancement on postcontrast T1-weighted images; 2) days 7–10: prominent T2 hyperintensity and contrast enhancement, ADC normalization/pseudonormalization; 3) up to 4 weeks: elevated ADC values, prominent enhancement on postcontrast images; 4) after 4 weeks: partial reversibility of T2 hyperintensity, ADC elevation, and resolution of contrast enhancement.

**CONCLUSIONS:** In a subgroup of patients with MS presenting soon after new symptom onset, a transient reduction of the ADC delineated a short and very early phase of MS lesion evolution. Subsequent pseudonormalization of the ADC occurred along with signs of the development of vasogenic edema.

**ABBREVIATIONS:** CIS = clinically isolated syndrome; EP = echo-planar; NAWM = normal-appearing white matter; RRMS = relapsing-remitting MS

**M**RI of newly developing MS lesions provides a window to the early pathology of MS. The development of new lesions has, therefore, been the focus of numerous MRI studies. Increased permeability of the BBB on postcontrast T1-weighted MRI and new hyperintensities on T2-weighted images are usually the earliest clearly visible conventional MRI signs of new lesions.<sup>1,2</sup> DWI investigates water mobility, which is increased in chronic lesions and in acute vasogenic edema in MS.<sup>3–5</sup> This increase is thought to reflect expanded extracellular space, even though the individual contributions from edema, demyelination, and axonal loss are yet unknown.<sup>6–8</sup> DWI also may detect reductions of normal water mobility, which is typically but not exclusively demonstrated in acute ischemic stroke.<sup>9,10</sup> Reductions in water mobility are identified as hyperintense DWI signal intensity and corresponding low signal intensity on maps of the ADC. Most MRI studies report an increased ADC in acute MS lesions. However in a relatively small number of patients with MS and acute disseminated encephalomyelitis, a reduction of the ADC in the very early phase in acute MS lesions has also been documented.<sup>7,11</sup> Several recent case studies have reported a reduced ADC in acute demyelinating lesions and have emphasized their stroke-

like ADC appearance.<sup>12–15</sup> The temporal evolution of the ADC signal intensity has been well characterized in acute ischemic stroke showing typical phases of an initial reduction, followed by a pseudonormalization and an ADC elevation in the sub-acute-to-chronic phases.<sup>9,16</sup>

In this study, we report the development of multiparametric MRI signal-intensity characteristics in hyperacute lesions of patients with MS with the main focus on the time course of the ADC signal intensity.

## Materials and Methods

### Patient Selection

A total of 72 patients who presented with an acute new symptom were investigated with MRI before steroid treatment. The patients had either definite MS or a CIS suggestive of central nervous system demyelination. Patients who showed a lesion with a reduced ADC that appeared suitable (>1 cm) for a quantitative analysis were followed with serial MRI after the initial examination. The study was designed for frequent follow-up MRI examinations during 4 months after the initial presentation. The study was approved by the local ethics committee, and informed consent was obtained in written form from all patients.

### MRI

Initial and follow-up MRI studies were performed on a 1.5T MRI system (Magnetom Sonata; Siemens, Erlangen, Germany). A standardized protocol was used in all patients: 1) transverse, coronal, and sagittal localizing sequences followed by transverse oblique contiguous 5-mm sections aligned with the inferior borders of the corpus callosum; 2) T2-weighted images; 3) T1-weighted images; 4) FLAIR

Received August 23, 2011; accepted after revision October 28.

From the Department of Neurology, UniversitätsMedizin Mannheim, University of Heidelberg, Mannheim, Germany.

Please address correspondence to Achim Gass, MD, Department of Neurology, UniversitätsMedizin Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1–3, 68135 Mannheim, Germany; e-mail: achim.gass@medma.uni-heidelberg.de



Indicates open access to non-subscribers at [www.ajnr.org](http://www.ajnr.org)

<http://dx.doi.org/10.3174/ajnr.A2975>

**Table 1: Summary of clinical data**

No.	Age (yr)/ Sex	Disease Duration/ Diagnosis	New Clinical Symptoms	Symptom Onset to MRI (days)	Max. ADC ↓	Treatment Acute/Prophylaxis	OCB
1	19/F	2 yr/RRMS	Right internuclear ophthalmoplegia	1	-41%	IV cortisone/interferon	+
2	21/F	1 yr/RRMS	Dysarthria	0	-66%	IV cortisone/-	+
3	20/F	1 yr/RRMS	Vertigo, left-sided numbness	1.5	-41%	IV cortisone/-	+
4	45/F	1.5 yr/RRMS	Right-sided weakness	2	-20%	IV cortisone/-	+
5	25/F	1 yr/RRMS	Dysarthria, right-sided weakness	4	-17%	IV cortisone/-	-
6	25/F	Initial presentation/CIS	Dysarthria, left-sided weakness and numbness	2	-51%	IV cortisone/-	+
7	30/F	1.5 yr/RRMS	Left-sided arm weakness	2	-16%	IV cortisone/-	+
8	33/F	0.5 yr/RRMS	Hemianopia	3	-22%	IV cortisone/-	+
9	31/M	1 yr/RRMS	N.V. numbness	1	-24%	IV cortisone/-	+
10	44/M	2 yr/RRMS	Right-sided weakness	3	-41%	IV cortisone/interferon	+

**Note:**—OCB indicates oligoclonal bands; +, positive OCB; -, negative OCB.

images; 5) DWI EP spin-echo images (TR/TE, 4000/110 ms;  $b = 0/500/1000$  s/mm<sup>2</sup>; FOV, 240 mm<sup>2</sup>; matrix size, 128 × 128; sequential application of 3 separate diffusion-sensitizing gradients in perpendicular directions); and 6) T1-weighted images 10 minutes after manual injection of single-dose contrast agent (gadoterate dimeglumine [Dotarem; Guerbet, Aulnay-sous-Bois, France]).

### Data Processing and Analysis


ADC maps were calculated on a pixel-by-pixel basis by a linear least-squares fit after averaging of the direction-dependent DWI. The ADC value was determined by manual ROI analysis. ADC values were compared with those in the corresponding NAWM of the contralateral hemisphere. Signal-intensity ratios in the respective ROIs were also recorded on conventional MRI.

### Results

Of the 72 patients with new acute symptoms, 10 showed a lesion with a reduced ADC that appeared suitable (>1 cm) for a quantitative analysis. The lesion size ranged from 1.2 to 2.1 cm in the largest diameter in the transverse plane. Most patients were in the early phase of RRMS and were not on immunomodulatory treatment at the time of their relapse. The presenting new symptoms and further clinical information are given in Table 1. The mean delay between symptom onset and the first MRI examination was 47 hours. The patients were subsequently examined serially 4–7 times (mean, 5) with an interval of 2 days to 5 months, resulting in 52 examinations in total. Most patients had recovered fully from their relapse symptoms at 4 months.

#### Time Course of the ADC in Acute MS Lesions

The acute lesions were hyperintense on DWI at the initial measurement with a corresponding reduction of the ADC value relative to the contralateral normal-appearing brain tissue in every case. The mean ADC of control regions in healthy-appearing white matter correlated with previously obtained ADC values in healthy controls (for stroke studies).<sup>17</sup> The ADC was lowest on the initial MRI in all 10 patients and ranged between -66% and -17% (mean, -33.9%). Subsequently, the ADC value was increased at the second time point, to reach a pseudonormalization between days 7 and 10. The longest duration of an ADC reduction was observed in patient 2 (10 days), who also showed the most pronounced ADC reduction initially. At time points later than 4 weeks, in 6/10



**Fig 1.** Time course of intralesional ADC values during the first 90 days in all 10 patients. Note that measurements outside the 90-day range are not shown for better visualization of early time points.


cases there was only a slight further increase of the ADC observed (Fig 1).

#### MRI Signal-Intensity Changes on Conventional MRI


On initial MRI, all lesions subject to analysis showed slight hyperintense signal intensity on T2-weighted images, which became more pronounced and increased in size (examples are shown in Figs 2 and 3) (Table 2). There was no enhancement on postcontrast T1-weighted images in 8/10 patients, while there was very slight contrast enhancement in 2/10 cases (patients 3 and 4), and it became more prominent, parallel to the ADC increase, sometimes parallel to the T2 signal-intensity hyperintensity. Reduced diffusion delineated a short very early phase of the evolution of symptomatic lesions. While lesions progressed to the typical acute edematous appearance (increase of T2 hyperintensity and contrast enhancement), the ADC increased parallel to pseudonormal and elevated values.

#### Intrinsic Acute MS Lesion Patterns

In 3 patients (patients 1, 2, and 4), a concentric arrangement of signal-intensity alterations and course was detected with a low ADC in the rim and an already increased ADC in the center of the lesion. This corresponded to a central enhancement,



**Fig 2.** Exemplary ADC, contrast-enhanced T1-weighted, DWI, and FLAIR images of the first 4 MRI time points of patient 4 during the first 14 days after new symptom onset. The initially low ADC is associated with only slight T2 hyperintensity. The increasing ADC signal intensity on follow-ups is paralleled by the development of prominent T2 hyperintensity. Contrast enhancement is minimal in the zone of reduced ADC initially and becomes very prominent at time points 3 and 4.



**Fig 3.** Exemplary ADC, DWI, contrast-enhanced T1-weighted, and T2-weighted images of the first 3 examinations of patient 9 in the first 15 days after new onset trigeminal sensory loss. The fascicular trigeminal fibers are affected by an acute lesion (circled in green). The lesion shows hyperintensity on DWI and a reduced ADC, while minimal T2 hyperintensity is noted without contrast enhancement on T1-weighted MRI initially. With time, the ADC pseudonormalizes and increases, while T2 hyperintensity and contrast enhancement become more prominent.

**Table 2: Intralesional signal change on ADC and T2-weighted images<sup>a</sup>**

Patient	Day						
Patient 1	Day 1	Day 8	Day 17	Day 55			
ADC	-41	10	21	50			
T2	17	18	25	43			
Patient 2	Day 0	Day 7	Day 14	Day 21	Day 49	Day 83	Day 207
ADC	-66	-44	-34	-18	72	37	36
T2	19	20	32	46	64	48	42
Patient 3	Day 1	Day 8	Day 35	Day 42			
ADC	-41	-7	47	41			
T2	15	80	86	35			
Patient 4	Day 2	Day 6	Day 10	Day 14	Day 85	Day 175	
ADC	-20	-15	-11	56	60	125	
T2	32	50	54	87	105	43	
Patient 5	Day 4	Day 12	Day 20	Day 29	Day 65		
ADC	-17	5	10	18	30		
T2	35	56	72	65	52		
Patient 6	Day 2	Day 6	Day 14	Day 28			
ADC	-51	-35	63	130			
T2	37	62	98	74			
Patient 7	Day 2	Day 10	Day 21	Day 30	Day 66	Day 106	
ADC	-16	5	45	50	102	105	
T2	23	45	86	73	66	65	
Patient 8	Day 3	Day 6	Day 9	Day 21	Day 64		
ADC	-22	-4	25	55	62		
T2	25	45	57	63	66		
Patient 9	Day 1	Day 8	Day 15	Day 21	Day 34		
ADC	-24	12	32	53	59		
T2	15	20	18	31	45		
Patient 10	Day 3	Day 15	Day 30	Day 37	Day 51	Day 66	
ADC	-41	-25	12	27	58	62	
T2	8	32	46	63	78	54	

<sup>a</sup> Values are given relative to the NAWM in the contralateral hemisphere.

which regressed and was followed by an enhancement of the rim of the lesion at the time of ADC pseudonormalization. The intensity of the T2 signal intensity varied accordingly with high central signal intensity and an intermediate T2 hyperintensity in the periphery of the lesion.

## Discussion

We searched for acute MS lesions with a reduced ADC and followed their evolution and signal-intensity changes serially. Our screening approach resulted in a highly selected lesion population that was identified in approximately 10/72 of the screened patients with acute MS. The subsequently detected time course of ADC change is interesting in several respects.

Several reports have demonstrated increased ADC values both in acute contrast-enhancing and chronic MS lesions as well as in the NAWM, confirming that diffusion measurements are sensitive for detecting pathologic changes associated with states of increased water mobility.<sup>3-5,8,18</sup> In chronic MS lesions, the ADC increase is highly variable (most pronounced ADC increase in T1 hypointense lesions) and higher than that in NAWM; this finding confirms the concept that the severity of tissue matrix damage of MS lesions is heterogeneous.<sup>8</sup> It has been suggested that inflammatory vasogenic edema, axonal loss, and demyelination are the most likely pathologic substrates of increased ADC.<sup>8</sup> Our results are in line with these reports because we also observed an increase of the ADC in the subacute stages of lesion development.

However, the main finding of this study is that a significant

ADC reduction of up to 66% can be present as a transient (2–7 days) finding in the earliest/hyperacute phase of MRI lesion development in MS. The results of the time course of lesions with a reduced ADC demonstrate clearly that there is a very narrow time window to detect such lesions. We recruited patients in this study with a particular focus on a very early MRI after the onset of a new symptom, and MRI was therefore performed as soon as possible after patients came to our attention. Only patients presenting early after symptom onset showed lesions with a reduced ADC. Along with the gradual development of signs of prominent inflammatory edematous changes, the phase of ADC reduction is followed by transient brief pseudonormalization and a subsequent increase of the ADC (3–7 days after symptom onset). The rather faint contrast enhancement and only mild T2 hyperintensity in the hyperacute phase in our series indicate that the increased permeability of the BBB and edematous tissue change were not fully developed at this point. Contrast enhancement showed both a change with time in that it became more prominent and/or a change in the spatial distribution of enhancement starting in the center of the lesion and progressing sometimes in a centrifugal direction to the rim of the lesion. This is in accordance with serial studies of plaque evolution on MRI in patients with MS showing a centrifugal evolution of pathologic processes.<sup>1</sup>

Two longitudinal studies that also used longer intervals between MRI examinations (minimum of 4 weeks) have observed increased ADC signal intensity in the lesions already at the first MRI.<sup>5,6</sup> We think that both patient selection and the time from symptom onset to the first MRI are important in this regard and that it might well be that the hyperacute phase was missed in these studies. Another cross-sectional study extrapolated different phases of lesion acuity by using DWI findings; however, this was done without the opportunity to ascertain DWI findings on serial analysis.<sup>11</sup>

ADC reduction in the acute phase of MS lesions has been reported in several recent case studies, some stressing the stroke-like appearance of their findings and resulting problems of differential diagnosis.<sup>12-15,19</sup> In contrast to MS, the evolution of the ADC has been analyzed in numerous studies in hyperacute ischemic stroke.<sup>9,16</sup> It may be for this reason that an ischemic mechanism has been suggested as involved in the ADC reduction. We would not share this view but favor another potential mechanism for the reduction of the ADC in MS. Lesion locations and clinical presentations of acute relapses in MS were very different from those in acute stroke. The location and extent of MS lesions did not match those in arterial vascular territories or lacunar stroke.

Comparing the ADC time course of MS lesions with that of acute ischemic lesions is also made difficult by the fact that the onset of symptoms in MS is not as acute as in stroke and can therefore not be identified with the same precision. This is reflected by our “symptom-to-MRI” times of days as opposed to a few hours in MRI studies of acute stroke. However, in contrast to a previous study of 2 patients with MS with a mild ADC reduction of 22%–33% in the acute lesions, we also found a pronounced ADC reduction in early lesions.<sup>10</sup>

It is known that ischemia is not a prerequisite for the development of lesions with a reduced ADC as studies in patients after prolonged epileptic seizures have clearly shown. In these patients, ADC reductions of 11%–37% have been demon-

strated, while signs of increased brain perfusion (due to the high energy demand) were noted in affected tissue.<sup>20</sup> A reduction of the ADC has been detected in different acute neurologic diseases (eg, stroke,<sup>21,22</sup> focal epilepsy,<sup>23</sup> toxic demyelination<sup>24</sup>). We would favor an inflammatory mechanism that could lead to disturbances of energy metabolism, namely mitochondrial dysfunction, and, in turn, lead to reduced diffusion. This would be in line with recent evidence that an aggressive inflammatory milieu including tumor necrosis factor- $\alpha$  and nitric oxide may lead to mitochondrial dysfunction and compromise of energy metabolism.<sup>25</sup> Furthermore, there is experimental evidence that lesions may exhibit a reduced ADC and contrast enhancement in central nervous system inflammation induced by intraparenchymal injection of interleukin-1.<sup>26</sup>

It is also interesting in this respect that lesions with a low ADC in our study correlated with clinical symptoms, which would be in line with mitochondrial dysfunction and subsequent electrical compromise. Theoretically, these events might even take place in the absence of demyelination, which may be more prominent in slightly later stages of the lesion development. ADC reduction is present before MRI signs of tissue destruction become prominent and might be predominantly related to parenchymal inflammation.

Most interesting, a new CSF marker of hypoxialike tissue damage in active MS lesions has recently been described, which may also point to a mechanism related to energy-metabolism compromise in MS lesions.<sup>27</sup> Further proposed hypotheses have been contributions from the presence of cytotoxic edema of oligodendroglia or hypercellularity in acute MS lesions.<sup>11</sup> These proposed mechanisms, disturbances of energy metabolism, and cytotoxic cell swelling and hypercellularity might well contribute to reduced diffusion.

## Conclusions

In a subgroup of patients with MS presenting early after new symptom onset, a transient reduction of the ADC delineated a short and very early phase of MS lesion evolution. Subsequent pseudonormalization of the ADC occurred along with signs of the development of vasogenic edema. Further studies in larger patient samples are necessary to confirm and elucidate whether the observed MRI findings indeed indicate a small subgroup of active lesions. Such studies may also clarify whether early MRI immediately after new symptoms will increase the detection rate of reduced diffusion in acute MS lesions.

Disclosures: Achim Gass—UNRELATED: Travel/Accommodations/Meeting Expenses Unrelated to Activities Listed: honoraria for lecturing, travel expenses for attending meetings, and financial support for research from Bayer Schering, Biogen Idec, Merck Serono, Novartis, and Teva Neurosciences.

## References

- Guttmann CR, Ahn SS, Hsu L, et al. **The evolution of multiple sclerosis lesions on serial MR.** *AJNR Am J Neuroradiol* 1995;16:1481–91
- Kermode AG, Thompson AJ, Tofts P, et al. **Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications.** *Brain* 1990;113(pt 5):1477–89
- Schaefer PW, Grant PE, Gonzalez RG. **Diffusion-weighted MR imaging of the brain.** *Radiology* 2000;217:331–45
- Horsfield MA, Larsson HB, Jones DK, et al. **Diffusion magnetic resonance imaging in multiple sclerosis.** *J Neurol Neurosurg Psychiatry* 1998;64(suppl 1):S80–84
- Castriota-Scanderbeg A, Sabatini U, Fasano F, et al. **Diffusion of water in large demyelinating lesions: a follow-up study.** *Neuroradiology* 2002;44:764–67
- Werring DJ, Brassat D, Droogan AG, et al. **The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study.** *Brain* 2000;123(pt 8):1667–76
- Roychowdhury S, Maldjian JA, Grossman RI. **Multiple sclerosis: comparison of trace apparent diffusion coefficients with MR enhancement pattern of lesions.** *AJNR Am J Neuroradiol* 2000;21:869–74
- Cercignani M, Iannucci G, Rocca MA, et al. **Pathologic damage in MS assessed by diffusion-weighted and magnetization transfer MRI.** *Neurology* 2000;54:1139–44
- Fiebach JB, Jansen O, Schellinger PD, et al. **Serial analysis of the apparent diffusion coefficient time course in human stroke.** *Neuroradiology* 2002;44:294–98
- Schlaug G, Siewert B, Benfield A, et al. **Time course of the apparent diffusion coefficient (ADC) abnormality in human stroke.** *Neurology* 1997;49:113–19
- Tievsky AL, Ptak T, Farkas J. **Investigation of apparent diffusion coefficient and diffusion tensor anisotropy in acute and chronic multiple sclerosis lesions.** *AJNR Am J Neuroradiol* 1999;20:1491–99
- Rosso C, Remy P, Creange A, et al. **Diffusion-weighted MR imaging characteristics of an acute stroke-like form of multiple sclerosis.** *AJNR Am J Neuroradiol* 2006;27:1006–08
- Przeklasa-Auth M, Ovbiagele B, Yim C, et al. **Multiple sclerosis with initial stroke-like clinicoradiologic features: case report and literature review.** *J Child Neurol* 2010;25:732–37
- Balashov KE, Aung LL, Dhib-Jalbut S, et al. **Acute multiple sclerosis lesion: conversion of restricted diffusion due to vasogenic edema.** *J Neuroimaging* 2011;21:202–04
- Bugnacourt JM, Garcia PY, Monet P, et al. **Teaching neuroimages: marked reduced apparent diffusion coefficient in acute multiple sclerosis lesion.** *Neurology* 2010;74:e87
- Munoz Maniega S, Bastin ME, Armitage PA, et al. **Temporal evolution of water diffusion parameters is different in grey and white matter in human ischaemic stroke.** *J Neurol Neurosurg Psychiatry* 2004;75:1714–18
- Gass A, Gaa J, Sommer A, et al. **Echo-planar diffusion-weighted MRI in the diagnosis of acute ischemic stroke: characterisation of tissue abnormalities and limitations in the interpretation of imaging findings [in German].** *Radio-loge* 1999;39:695–702
- Rocca MA, Cercignani M, Iannucci G, et al. **Weekly diffusion-weighted imaging of normal-appearing white matter in MS.** *Neurology* 2000;55:882–84
- Rovira A, Pericot I, Alonso J, et al. **Serial diffusion-weighted MR imaging and proton MR spectroscopy of acute large demyelinating brain lesions: case report.** *AJNR Am J Neuroradiol* 2002;23:989–94
- Szabo K, Poepl E, Pohlmann-Eden B, et al. **Diffusion-weighted and perfusion MRI demonstrates parenchymal changes in complex partial status epilepticus.** *Brain* 2005;128:1369–76
- Lovblad KO, Baird AE, Schlaug G, et al. **Ischemic lesion volumes in acute stroke by diffusion-weighted magnetic resonance imaging correlate with clinical outcome.** *Ann Neurol* 1997;42:164–70
- Warach S, Dashe JF, Edelman RR. **Clinical outcome in ischemic stroke predicted by early diffusion-weighted and perfusion magnetic resonance imaging: a preliminary analysis.** *J Cereb Blood Flow Metab* 1996;16:53–59
- Wiesmann UC, Symms MR, Shorvon SD. **Diffusion changes in status epilepticus.** *Lancet* 1997;350:493–94
- McKinney AM, Kieffer SA, Paylor RT, et al. **Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging.** *AJR Am J Roentgenol* 2009;193:192–206
- Su KG, Banker G, Bourdette D, et al. **Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis.** *Curr Neurol Neurosci Rep* 2009;9:411–17
- Blamire AM, Anthony DC, Rajagopalan B, et al. **Interleukin-1 $\beta$ -induced changes in blood-brain barrier permeability, apparent diffusion coefficient, and cerebral blood volume in the rat brain: a magnetic resonance study.** *J Neurosci* 2000;20:8153–59
- Lassmann H, Reindl M, Rauschka H, et al. **A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions.** *Brain* 2003;126:1347–57